- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00197015
Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children
July 2, 2018 updated by: GlaxoSmithKline
Immunogenicity & Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With Merck & Company, Inc. Measles-Mumps-Rubella Vaccine (M-M-RII) & Merck & Co Varicella Vaccine (VARIVAX™) to Children 15 Months of Age
This is a study to evaluate the immune response and safety of GSK Biologicals 2-dose inactivated hepatitis A vaccine when administered with a measles/mumps/rubella vaccine and a varicella (chickenpox) vaccine in children as young as 15 months of age.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
An open, controlled comparison of Havrix™ administered alone or with MMR II and Varivax™.
The three groups evaluated are: 1) Havrix™ alone, 2) Havrix™ + MMR II and Varivax™ and 3) MMR II and Varivax™ followed by Havrix™ one month later.
Study Type
Interventional
Enrollment (Actual)
1474
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arkansas
-
Cabot, Arkansas, United States, 72023
- GSK Investigational Site
-
Jonesboro, Arkansas, United States, 72401
- GSK Investigational Site
-
North Little Rock, Arkansas, United States, 72117
- GSK Investigational Site
-
-
California
-
Huntington Beach, California, United States, 92647
- GSK Investigational Site
-
Oakland, California, United States, 94609
- GSK Investigational Site
-
Rolling Hills Estates, California, United States, 90274
- GSK Investigational Site
-
-
Connecticut
-
Norwich, Connecticut, United States, 06360
- GSK Investigational Site
-
-
Florida
-
Jacksonville, Florida, United States, 32209
- GSK Investigational Site
-
-
Georgia
-
Marietta, Georgia, United States, 30062
- GSK Investigational Site
-
-
Iowa
-
Waterloo, Iowa, United States, 50702
- GSK Investigational Site
-
Waukee, Iowa, United States, 50263
- GSK Investigational Site
-
-
Kentucky
-
Lexington, Kentucky, United States, 40503
- GSK Investigational Site
-
-
Louisiana
-
Bossier City, Louisiana, United States, 71111
- GSK Investigational Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- GSK Investigational Site
-
-
Nevada
-
Henderson, Nevada, United States, 89015
- GSK Investigational Site
-
Las Vegas, Nevada, United States, 89014
- GSK Investigational Site
-
-
New York
-
Albany, New York, United States, 12208
- GSK Investigational Site
-
Brooklyn, New York, United States, 11203
- GSK Investigational Site
-
Rochester, New York, United States, 14620
- GSK Investigational Site
-
Syracuse, New York, United States, 13210
- GSK Investigational Site
-
-
North Carolina
-
Lumberton, North Carolina, United States, 28358
- GSK Investigational Site
-
Sylva, North Carolina, United States, 28779
- GSK Investigational Site
-
-
Ohio
-
Cleveland, Ohio, United States, 44109
- GSK Investigational Site
-
University Heights, Ohio, United States, 44118
- GSK Investigational Site
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74104
- GSK Investigational Site
-
-
Pennsylvania
-
Beaver Falls, Pennsylvania, United States, 15010
- GSK Investigational Site
-
Norristown, Pennsylvania, United States, 19401
- GSK Investigational Site
-
Pittsburgh, Pennsylvania, United States, 15241
- GSK Investigational Site
-
Pittsburgh, Pennsylvania, United States, 15213
- GSK Investigational Site
-
Rydal, Pennsylvania, United States, 19046
- GSK Investigational Site
-
Sellersville, Pennsylvania, United States, 18960
- GSK Investigational Site
-
-
Rhode Island
-
Warwick, Rhode Island, United States, 02886
- GSK Investigational Site
-
-
Tennessee
-
Bristol, Tennessee, United States, 37620
- GSK Investigational Site
-
Kingsport, Tennessee, United States, 37660
- GSK Investigational Site
-
Kingsport, Tennessee, United States, 37664
- GSK Investigational Site
-
-
Texas
-
Austin, Texas, United States, 78758
- GSK Investigational Site
-
San Antonio, Texas, United States, 78205-2489
- GSK Investigational Site
-
Temple, Texas, United States, 76508
- GSK Investigational Site
-
-
Utah
-
Layton, Utah, United States, 84041
- GSK Investigational Site
-
South Jordan, Utah, United States, 84095
- GSK Investigational Site
-
-
Virginia
-
Norfolk, Virginia, United States, 23510
- GSK Investigational Site
-
-
Wisconsin
-
Marshfield, Wisconsin, United States, 54449
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 1 year (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects whose parents/guardians are believed by the investigator to be willing to comply with the requirements of the protocol
- A male or female child 12 and 13 months of age at the time of entry into the Enrollment Phase
- Written informed consent obtained from the parents or guardian of the subject,
- Free of obvious health problems as established by medical history and history-directed physical examination before entering into the study, and
- Parents/guardian of the subject must have a telephone or be able to be contacted by telephone
Exclusion Criteria:
- Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 42 days preceding the first dose of study vaccine, or planned use during the study period, Chronic administration (defined as more than 14 days) of immuno-suppressant or other immune-modifying drugs within six months prior to vaccination or planned administration at any time during the study period. (For corticosteroids, this will mean prednisone, or equivalent, ≥0.5 mg/kg/day. Inhaled, nasal and topical steroids are allowed.) Planned administration or administration of any vaccine not foreseen by the study protocol during the period 31 days before and 31 days after each dose of study vaccine(s).
- Previous vaccination against hepatitis A,
- History of hepatitis A,
- Known exposure to hepatitis A,
- Previous vaccination against measles, mumps, rubella and/or varicella,
- History of measles, mumps, rubella and/or varicella,
- Known exposure to measles, mumps, rubella and/or varicella within 30 days prior to the start of the study,
- Planned chronic use of salicylates during the 6-week period following administration of the doses of study vaccine(s),
- Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection,
- A family history of congenital, hereditary or infectious immunodeficiency or parental risk factors for HIV infection,
- History of allergic disease/reactions or hypersensitivity likely to be exacerbated by any component of HavrixTM, M-M-RII or VARIVAXTM, including 2-phenoxyethanol, neomycin and gelatin,
- History of anaphylactic or anaphylactoid reactions to egg proteins,
- History of hypersensitivity/allergic reaction to latex. Note: The tip cap and the rubber plunger of the HavrixTM needleless pre-filled syringes contain dry natural latex rubber.
- Major congenital defects or serious chronic illness,
- Active untreated tuberculosis,
- History of significant blood dyscrasias
- History of any neurologic disorder (a history of febrile seizures not associated with an underlying neurological disorder does not exclude the subject)
- Acute disease at the time of vaccination
- Administration of immunoglobulins and/or any blood products within three months prior to the first dose of study vaccine or planned administration at any time during the entire study period
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: HAV Group
Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)
|
2 doses administered intramuscularly
|
Experimental: HAV+MMR+V Group
Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9
|
2 doses administered intramuscularly
1 dose administered subcutaneously
1 dose administered subcutaneously
|
Active Comparator: MMR+V→HAV Group
Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)
|
2 doses administered intramuscularly
1 dose administered subcutaneously
1 dose administered subcutaneously
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups.
Time Frame: 31 days following the second dose of Havrix®
|
Concentrations are given as geometric mean concentrations (GMCs) expressed as milli-international units per milliliter (mIU/mL).
|
31 days following the second dose of Havrix®
|
Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentration Equal or Above the Cut-off Value in HAV and HAV+MMR+V Groups
Time Frame: 31 days following the second dose of Havrix®
|
Anti-HAV antibody cut-off value assessed include 15 milli-international units per milliliter (mIU/mL).
|
31 days following the second dose of Havrix®
|
Number of Subjects Seroconverted for Anti-measle, Anti-mumps and Anti-varicella Antibodies in HAV+MMR+V and MMR+V→HAV Groups
Time Frame: 42 days following the administration of M-M-R®II and VARIVAX®
|
Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination.
Cut-off values assessed include 150 milli-international units per milliliter (mIU/mL) for anti-measles antibodies, 28 Effective Dose 50 (ED50) for anti-mumps antibodies and 1:5 for anti-varicella antibodies.
|
42 days following the administration of M-M-R®II and VARIVAX®
|
Number of Subjects With Vaccine Response for Anti-rubella Antibodies in HAV+MMR+V and MMR+V→HAV Groups
Time Frame: 42 days following administration of M-M-R®II and VARIVAX®
|
Vaccine response is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination.
Cut-off value assessed include 10 milli-international units per milliliter (mIU/mL).
|
42 days following administration of M-M-R®II and VARIVAX®
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-measles, Anti-mumps, Anti-rubella and Anti-varicella Antibody Titers in HAV+MMR+V and MMR+V→HAV Groups
Time Frame: 42 days following the administration of M-M-R®II and VARIVAX®
|
Titers are given as geometric mean titers (GMTs).
|
42 days following the administration of M-M-R®II and VARIVAX®
|
Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups
Time Frame: 42 days following the first dose of Havrix®
|
Concentrations are given as geometric mean concentrations (GMCs).
|
42 days following the first dose of Havrix®
|
Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentration Equal or Above the Cut-off Value in HAV and HAV+MMR+V Groups
Time Frame: 42 days following the first dose of Havrix®
|
Anti-HAV antibody cut-off value assessed include 15 milli-international units per millilitre (mIU/mL).
|
42 days following the first dose of Havrix®
|
Anti-hepatitis A Virus (HAV) Antibody Concentrations in MMR+V→HAV Group
Time Frame: 31 days following the second dose of Havrix®
|
Concentrations are given as geometric mean concentrations (GMCs).
|
31 days following the second dose of Havrix®
|
Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentrations Above the Cut-off Value in MMR+V→HAV Group
Time Frame: 31 days following the second dose of Havrix®
|
Anti-HAV antibody cut-off value assessed include 15 milli-international units per millilitre (mIU/mL).
|
31 days following the second dose of Havrix®
|
Number of Subjects With Vaccine Response to Havrix®
Time Frame: 31 days following the second dose of Havrix®
|
Vaccine response was defined as: 1) a detectable anti-hepatitis A virus (HAV) antibody concentration 31 days following the second dose in subjects who were initially seronegative; and 2) a 2-fold increase in anti-HAV antibody concentrations above the pre-study concentration 31 days following the second dose in subjects who were initially seropositive.
|
31 days following the second dose of Havrix®
|
Number of Subjects Reporting Solicited Local Symptoms
Time Frame: During the 4-day period following each dose of vaccine
|
Solicited local symptoms assessed include pain, rash (local), redness and swelling.
|
During the 4-day period following each dose of vaccine
|
Number of Subjects Reporting Solicited General Symptoms
Time Frame: During the 4-day period following each dose of vaccine
|
Solicited general symptoms assessed include drowsiness, fever, irritability, loss of appetite and rash (general).
|
During the 4-day period following each dose of vaccine
|
Number of Subjects Reporting Measles, Mumps, Rubella and Varicella Specific Solicited General Adverse Events
Time Frame: During the 43-day period following each dose of vaccine
|
Specific adverse events assessed include papules, vesicles, crusts, parotid/salivary gland swelling and suspected signs of meningitis/febrile seizures.
|
During the 43-day period following each dose of vaccine
|
Number of Subjects Reporting Unsolicited Adverse Events (AEs)
Time Frame: During the 31-day period following each dose of vaccine
|
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms
|
During the 31-day period following each dose of vaccine
|
Number of Subjects Reporting Serious Adverse Events (SAEs)
Time Frame: During the Active Phase (from Day 0 up to Day 31 after the second dose) and the Extended Safety Follow-up Phase of the study (from Day 31 after the second dose up to study end)
|
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
|
During the Active Phase (from Day 0 up to Day 31 after the second dose) and the Extended Safety Follow-up Phase of the study (from Day 31 after the second dose up to study end)
|
Number of Subjects Reporting New Chronic Illnesses
Time Frame: During the Active Phase (from Day 0 up to Day 31 after the second dose) and the Extended Safety Follow-up Phase of the study (from Day 31 after the second dose up to study end)
|
New Chronic illnesses include autoimmune disorders, asthma, type I diabetes, allergies.
|
During the Active Phase (from Day 0 up to Day 31 after the second dose) and the Extended Safety Follow-up Phase of the study (from Day 31 after the second dose up to study end)
|
Number of Subjects Reporting Medically Significant Events
Time Frame: During the Active Phase (from Day 0 up to Day 31 after the second dose) and the Extended Safety Follow-up Phase of the study (from Day 31 after the second dose up to study end)
|
Medically significant events include, but are not limited to, diabetes, autoimmune disease, asthma, allergies and/or conditions prompting emergency room or physician office visits that are not related to well-child care, vaccination or common acute illnesses (e.g., upper respiratory infection, otitis media, pharyngitis, gastroenteritis, injury and visits for routine physical examination).
|
During the Active Phase (from Day 0 up to Day 31 after the second dose) and the Extended Safety Follow-up Phase of the study (from Day 31 after the second dose up to study end)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 6, 2003
Primary Completion (Actual)
June 9, 2009
Study Completion (Actual)
June 9, 2009
Study Registration Dates
First Submitted
September 13, 2005
First Submitted That Met QC Criteria
September 13, 2005
First Posted (Estimate)
September 20, 2005
Study Record Updates
Last Update Posted (Actual)
July 31, 2018
Last Update Submitted That Met QC Criteria
July 2, 2018
Last Verified
October 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Liver Diseases
- Hepatitis, Viral, Human
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Herpesviridae Infections
- Varicella Zoster Virus Infection
- Togaviridae Infections
- Rubivirus Infections
- Hepatitis
- Hepatitis A
- Chickenpox
- Rubella
Other Study ID Numbers
- 208109/231
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Study Data/Documents
-
Clinical Study Report
Information identifier: 208109/231Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: 208109/231Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Dataset Specification
Information identifier: 208109/231Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: 208109/231Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: 208109/231Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: 208109/231Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis A
-
Boryung Pharmaceutical Co., LtdCompletedHepatitis A VaccineKorea, Republic of
-
Merck Sharp & Dohme LLCCompletedHepatitis A Virus Infection
-
Sanofi Pasteur, a Sanofi CompanyCompletedHepatitis A | Hepatitis A VirusChina
-
Boryung Pharmaceutical Co., LtdCompletedHepatitis A VaccineKorea, Republic of
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedHepatitis | Acute Hepatitis APanama
-
Grifols Therapeutics LLCCompletedAnti-Hepatitis A Antibody Levels in Heathy SubjectsUnited States
-
Boryung Biopharma Co., Ltd.Not yet recruitingHepatitis A | Hep AKorea, Republic of, Thailand
-
Merck Sharp & Dohme LLCCompleted
-
University of Maryland, BaltimoreAlexandria University; MADAUS GmbH; The Egyptian Company for Blood Transfusion... and other collaboratorsTerminatedAcute Hepatitis C | Acute Hepatitis B | Acute Hepatitis A | Acute Hepatitis E | Acute EBV Hepatitis | Acute CMV HepatitisEgypt
Clinical Trials on Havrix®
-
Canadian Immunization Research NetworkUniversity of British Columbia; University of Calgary; Dalhousie University; Université...Completed
-
Sinovac Biotech Co., LtdCompleted
-
Sinovac Biotech Co., LtdCompleted
-
GlaxoSmithKlineCompletedNeisseria Meningitidis | Haemophilus Influenzae Type bUnited States
-
GlaxoSmithKlineCompletedMeasles | Rubella | Mumps | VaricellaUnited States
-
GlaxoSmithKlineCompletedMeasles | Rubella | Mumps | Measles-Mumps-Rubella VaccineUnited States, Puerto Rico
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineTerminatedTetanus | Diphtheria | Acellular PertussisAustralia